Journal
PHARMACOGENOMICS
Volume 20, Issue 17, Pages 1235-1245Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2019-0121
Keywords
gene polymorphism; methotrexate; pharmacogenetics; rheumatoid arthritis
Categories
Funding
- Ministry of Education, Science and Technological Development of the Republic of Serbia [175091]
Ask authors/readers for more resources
For many decades, methotrexate (MXT) has remained the drug of choice in the treatment of rheumatoid arthritis (RA). Unfortunately, a considerable number of patients do not achieve an appropriate therapeutic response. Pharmacogenetics studies do not give usable results regarding differences in MTX response among RA patients. The mechanism of MTX action in RA is not completely understood. We present and discuss data regarding the molecular basis of folate and adenosine pathways, the most obvious MTX targets, to explain possible causes of therapy failure. The molecular basis of the disease could also have an impact on therapy outcomes and in this review we explore this. Finally, we make a short review of available pharmacogenetics study results.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available